Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9;12(12):2039.
doi: 10.3390/jpm12122039.

Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial

Laith Alrubaiy  1   2 , Hayley A Hutchings  2 , Andrea Louca  2 , Frances Rapport  2   3 , Alan Watkins  2 , Shaji Sebastian  4 , John G Williams  2
Affiliations

Quality of Life in Patients with Acute Severe Ulcerative Colitis: Long-Term Follow-Up Results from the CONSTRUCT Trial

Laith Alrubaiy et al. J Pers Med. .

Abstract

Background: there is currently limited research examining the QoL of patients with Ulcerative colitis (UC) following treatment of acute severe colitis (ASUC).

Objective: to examine the long-term QoL of ASUC patients enrolled in the CONSTRUCT trial following treatment of UC with infliximab or ciclosporin and to compare the differences in the QoL between the two drug treatments over time.

Methods: The CONSTRUCT trial examined the cost and clinical effectiveness of infliximab and ciclosporin treatments for acute severe UC. We collected QoL questionnaire data from patients during the active trial period up to 36 months. Following trial completion, we contacted patients postannually for up to a maximum of 84 months. We collected QoL data using a disease-specific (CUCQ, or CUCQ+ for patients who had colectomy surgery) or generic (EQ5D-3L) questionnaire. We analysed QoL scores to determine if there was any difference over time and between treatments in generic or disease-specific QoL.

Results: Following initial treatment with infliximab and ciclosporin, patients experienced a statistically significant improvement in both the generic and disease-specific QoL at three months. Generic scores remained fairly static for the whole follow-up period, reducing only slightly up to 84 months. Disease-specific scores showed a much sharper improvement up to 2 years with a gradual reduction in QoL up to 84 months. Generic and disease-specific QoL remained higher than baseline values. There was no significant difference between treatments in any of the QoL scores.

Conclusions: Both infliximab and ciclosporin improve QoL following initial treatment for ASUC. QoL scores remain higher than at admission up to 84 months post-treatment.

Keywords: CUCQ; EQ5D; ciclosporin; infliximab; quality of life (QoL); ulcerative colitis (UC).

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare. This study was funded (in part) by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, grant number 06/78/03. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NIHR.

Figures

Figure 1
Figure 1
Mean (95% CI) quality of life profiles over time in the infliximab and ciclosporin groups for the EQ5D VAS, EQ5D score and CUCQ/CUCQ+.
See this image and copyright information in PMC

References

    1. Ordas I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet. 2012;380:1606–1619. doi: 10.1016/S0140-6736(12)60150-0. - DOI - PubMed
    1. Loftus E.V., Sandborn W.J. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 2002;31:1–20. doi: 10.1016/S0889-8553(01)00002-4. - DOI - PubMed
    1. Irvine E.J. Quality of life of patients with ulcerative colitis: Past, present, and future. Inflamm. Bowel Dis. 2008;14:554–565. doi: 10.1002/ibd.20301. - DOI - PubMed
    1. Moradkhani A., Beckman L.J., Tabibian J.H. Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors. J. Crohns Colitis. 2013;7:467–473. doi: 10.1016/j.crohns.2012.07.012. - DOI - PubMed
    1. Hutchings H.A., Alrubiay L., Watkins A., Cheung W.Y., Seagrove A.C., Williams J.G. Validation of the Crohn’s and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis. UEG J. 2017;5:571–578. doi: 10.1177/2050640616671627. - DOI - PMC - PubMed

LinkOut - more resources